Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $1.4152W HIGH $26.90
Volume
27.67 K
Value Traded
47.81 K
Short % Float
2.21%
Days to Cover
1.0
+5.63%Week
-17.95%1 Month
+63.17%3 Month
-54.67%6 Month
-99.84%5 Year
-100%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
3.87 M
EPS (TTM)
-9.76
P/E Ratio
-
Ent. Value
-1.06 M
Total Shares
711.14 K
Float Shares
1.49 M
Insiders
6.98%
Institutions
5.97%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
AEMD Catalyst Timeline
Dated clinical, regulatory and corporate events for Aethlon Medical, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Aethlon Medical, Inc.
700Total events
2Upcoming
89Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
●Quarterly UpdateCorporate
Conference call to review financial results and corporate developments
▲PublicationHemopurifier®FiledPresentation
Manuscript on extracellular vesicles in Long COVID accepted for publication in International Journal of Molecular Sciences
Long COVIDsource ↗
▼Equity OfferingCorporate
Raised approximately $4.0 million in gross proceeds through public offering of common stock
▲Timing GuidanceHemopurifier®FiledPresentation
Early biomarker signals from initial cohorts support continuing evaluation
oncologysource ↗
◆Enrollment CompleteHemopurifier®FiledTrial
Enrollment in third cohort underway
advanced solid tumorssource ↗
▲First Patient DosedHemopurifier®FiledTrial
First participant dosed in third and final cohort of Phase 1 oncology study in Australia
oncologysource ↗
▲PublicationHemopurifier®FiledPresentation
Publication of peer-reviewed study on mannosylated extracellular vesicles in Long COVID
Long COVIDsource ↗
▲Enrollment MilestoneHemopurifier®FiledTrial
First participant in Cohort 3 enrolled and treated with three Hemopurifier treatments
solid tumorssource ↗
▲ATM ProgramCorporate
Raised approximately $1.85 million in net proceeds through at-the-market program
●Oral PresentationPresentation
Conference call to review financial results and corporate developments
▲Enrollment CompleteHemopurifier®FiledTrial
Enrollment and treatment of participants in Cohort 2 completed
solid tumorssource ↗
▲DSMB ReviewHemopurifier®FiledTrial
DSMB review of Cohort 2 data recommended advancing to Cohort 3
solid tumorssource ↗
▲Patent GrantedHemopurifier®FiledIP / Competition
Patents issued in US and Europe for Hemopurifier applications in coronavirus-related conditions
long COVID and other coronavirus-related conditionssource ↗
●Preclinical PoCHemopurifier®FiledPreclinical
Advanced preclinical research evaluating Hemopurifier in rheumatoid arthritis and chronic kidney disease
rheumatoid arthritis and chronic kidney diseasesource ↗
●Other Regulator MilestoneHemopurifier®FiledEx-US Regulatory
Confirmed continued availability of FDA-authorized expanded access protocol for Ebola
Ebola virus diseasesource ↗
▲Enrollment CompleteHemopurifier®FiledTrial
Completed enrollment and treatment of participants in Cohort 2 of the Australian oncology study
solid tumorssource ↗
▲DSMB ReviewHemopurifier®FiledTrial
Independent Data Safety Monitoring Board reviewed Cohort 2 data and recommended advancing to Cohort 3
solid tumorssource ↗
▲Patent GrantedHemopurifier®FiledIP / Competition
Issuance of patents in the United States and Europe covering applications for long COVID and other coronavirus-related conditions
coronavirus-related conditionssource ↗
▲DSMB ReviewTrial
DSMB completed safety review of second cohort and recommended advancing to third and final cohort
solid tumorssource ↗
▲Enrollment CompleteHemopurifier®FiledTrial
Completed second cohort of Australian oncology trial
oncologysource ↗
●Quarterly UpdateCorporate
Conference call to review financial results and corporate developments
▲Enrollment UpdateHemopurifier®FiledTrial
Enrollment and treatment of Cohort 2 actively underway
solid tumorssource ↗
●Manufacturing MilestoneHemopurifier®FiledCMC / Inspection
Stavro evaluating Hemopurifier compatibility with SLAMB system
●Preclinical PoCHemopurifier®FiledPreclinical
Pre-clinical Long COVID research published on bioRxiv and submitted for peer review
Long COVIDsource ↗
▼Equity OfferingCorporate
Private placement priced at-the-market for $3.3 million gross proceeds
▲Preclinical PoCHemopurifier®FiledPreclinical
Publication of preclinical study showing GNA affinity resin binds extracellular vesicles in Long COVID samples
Long COVIDsource ↗
●Quarterly UpdateCorporate
Conference call to review financial results and corporate developments
▲Enrollment UpdateHemopurifier®FiledTrial
Recruitment begun for second cohort of Australian oncology trial
solid tumorssource ↗
●Biomarker DataHemopurifier®FiledClinical Data
Preliminary changes in extracellular vesicles, microRNAs, and lymphocytes in first patient cohort
cancer not responding to anti-PD-1 therapysource ↗
▲Patent GrantedHemopurifier®FiledIP / Competition
US Patent No. 12,409,260 directed to treatment of Long COVID to issue
Long COVIDsource ↗
◆Biomarker DataHemopurifier®FiledClinical Data
Data on extracellular vesicle removal and T cell activity expected
solid tumors not responding to anti-PD-1 antibodiessource ↗
◆Topline ReadoutHemopurifier®FiledClinical Data
Preliminary data from first cohort expected
solid tumors unresponsive to anti-PD-1 agentssource ↗
●Quarterly UpdateCorporate
Conference call to review financial results and corporate developments
▼Program DiscontinuationHemopurifier®FiledCorporate
Decision not to proceed with India oncology study
solid tumors (India study)source ↗
◆Poster PresentationHemopurifier®FiledPresentation
Poster presentation at Keystone Symposium on Long COVID
Long COVIDsource ↗
●Other Regulator MilestoneHemopurifier®FiledEx-US Regulatory
Ethics approval valid until August 6, 2025
solid tumors not responding to anti-PD-1 antibodiessource ↗
◆Poster PresentationHemopurifier®FiledPresentation
Poster presentation at Keystone Symposium on Long COVID
Long COVIDsource ↗
▲DSMB ReviewTrial
DSMB completed scheduled safety review and recommended advancing to next cohort
solid tumorssource ↗
▲DSMB ReviewHemopurifier®FiledTrial
DSMB recommended advancing to second treatment cohort
solid tumors unresponsive to anti-PD-1 immunotherapysource ↗
▲Patent GrantedHemopurifier®FiledIP / Competition
Unitary European Patent 4136453 directed to treatment of CAC issued
COVID-19-associated coagulopathy (CAC)source ↗
Past FDA Catalysts and PDUFA Decisions
How AEMD actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| - | Example Drug | Phase 3 data readout | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
No drug pipeline
Aethlon Medical, Inc. is a medical device company. The clinical trials it takes part in test other companies' drugs, so it has no drug pipeline of its own to score.
Clinical Trial Results
Readouts, endpoints and source filings for every AEMD program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Hemopurifier Breakthrough | cancer not responding to anti-PD-1 therapy | 2025-10-07 | changes in extracellular vesicles; changes in microRNAs; changes in lymphocyte countsRead More | Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical TrialRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Shah ChetanDirector | Disposition | -2,182 20,840 held | $0.82 | 06/30/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in AEMD
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Ikarian Capital, LLC | 0 % | 11.83 K | 14.36 K |
AEMD Institutional Ownership Trends
AEMD Short Interest
Shares sold short, counted twice a month.
2.21%
Short % of Float
of tradable shares sold short
32.9K
Shares Sold Short
-56.4% vs prior count
1.0 Low
Days to Cover
trading days of normal volume to buy every short share back
57.3K
Avg Daily Volume
the average used for days to cover
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How AEMD ranks across every disease it competes in
Competitive Position is a premium feature
See how AEMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialAEMD News
AEMD▲ +374.1%on this newsshared move
Aethlon Medical & North Immunology Announce Merger to Advance Novel IL-13 x IL-18 Bispecific Antibody for Atopic Dermatitis
Aethlon Medical has announced a merger with North Immunology to develop NOR-101, a bispecific antibody targeting atopic dermatitis. The merger is supported by a $180 million private placement, expected to fund operations until 2028. The Phase 1a study for NOR-101 is anticipated to start in Q1 2027, with significant data readouts planned for 2028.
Read more →AEMDAethlon Medical Reports Q1 Fiscal 2027 Results and Progress on Hemopurifier® Program
Aethlon Medical reported its Q1 fiscal 2027 results, highlighting advancements in its clinical programs, including the dosing of the first participant in the final cohort of its Phase 1 oncology study. The company also announced the acceptance of a manuscript on Long COVID for publication, supporting the scientific basis for its Hemopurifier. Financially, Aethlon raised $4 million post-quarter, although it noted ongoing operating losses and cash resource concerns.
Read more →AEMD▼ -7.7%on this news
Aethlon Medical to Release First Quarter Financial Results and Host Conference Call on August 13, 2026
Aethlon Medical, Inc. will announce its fiscal first quarter financial results on August 13, 2026, at 4:15 p.m. ET. Following the announcement, a conference call will be held at 4:30 p.m. ET to discuss the results and corporate developments. The Hemopurifier, a key product, is designed to treat cancer and viral infections and has received FDA Breakthrough Device designation.
Read more →AEMD▼ -5.5%on this news
Aethlon Medical Continues to Observe Directional Changes in Second Cohort of Australian Oncology Clinical Trial Evaluating Hemopurifier®
Aethlon Medical reported that the second cohort of its Australian oncology trial showed biological changes consistent with the first cohort after treatment with the Hemopurifier. These findings support the ongoing clinical program and the enrollment of a third cohort. The company plans an independent statistical analysis to evaluate the potential dose-response relationship of the treatment. However, the results are preliminary and do not yet demonstrate clinical efficacy.
Read more →AEMD▲ +11.3%on this news
Aethlon Medical Announces Pricing of $4.0 Million Follow-On Offering Priced At-The-Market Under NASDAQ Rules
Aethlon Medical, Inc. has announced the pricing of a follow-on offering of 5,633,009 shares at $0.7101 per share, expected to close on July 7, 2026. The offering aims to raise approximately $4.0 million to fund general corporate purposes, including R&D and clinical trials. The company is also focused on developing its Hemopurifier device for cancer and viral infections.
Read more →AEMDAethlon Medical Announces Publication Demonstrating Novel Long COVID Biomarker and Potential Therapeutic Target for the Hemopurifier®
Aethlon Medical announced a peer-reviewed study revealing that Long COVID patients have elevated levels of mannosylated extracellular vesicles. These vesicles can be captured by the Hemopurifier, suggesting its potential as a treatment for Long COVID. The findings support further research into the Hemopurifier's applications across various diseases.
Read more →AEMDAethlon Medical Announces Fiscal Year End
Aethlon Medical reported its financial results for the fiscal year ending March 31, 2026, along with updates on its Australian oncology study. The company has advanced to Cohort 3 in its clinical trial, where the first participant has been treated successfully. Significant progress has also been made in strengthening the company's intellectual property portfolio, particularly in areas related to long COVID and other coronavirus conditions. Despite achieving clinical milestones, Aethlon continues to experience financial losses and a need for careful management of its operating expenses.
Read more →AEMDAethlon Medical Announces Fiscal Year End March 31, 2026 Financial Results and Corporate Update
Aethlon Medical reported its fiscal year-end results for March 31, 2026, highlighting advancements in its Australian oncology study, which has now entered its third dosing cohort. The company also expanded its Hemopurifier intellectual property portfolio and achieved a significant reduction in operating expenses. Despite these advancements, Aethlon continues to face substantial net losses and limited cash reserves.
Read more →AEMD▼ -8.3%on this news· ran to -21% by day 3
Aethlon Medical to Release Fiscal Year End Financial Results and Host Conference Call on June 10, 2026
Aethlon Medical, Inc. will announce its fiscal year-end financial results on June 10, 2026, followed by a conference call to discuss the results and recent developments. The Hemopurifier, a key product in their pipeline, has shown promise in clinical studies for treating cancer and life-threatening viral infections. Interested parties can register for the call or access a replay afterward.
Read more →AEMDAethlon Medical Monitoring Current Ebola Outbreak and Reaffirms Outbreak/Pandemic Preparedness
Aethlon Medical is monitoring the Bundibugyo Ebola virus outbreak in the Democratic Republic of the Congo and Uganda, reaffirming its preparedness to engage with healthcare authorities regarding its Hemopurifier technology. The device has shown potential in past cases, although it remains investigational for Ebola treatment. The company emphasizes the need for broad-spectrum therapies in the face of limited approved treatments.
Read more →AEMD▼ -6.1%on this news
Aethlon Medical, Inc. Advances to Final Cohort in Oncology Clinical Trial Following Positive DSMB Review
Aethlon Medical, Inc. has received a positive recommendation from the Data Safety Monitoring Board (DSMB) to advance to the final cohort of its clinical trial for the Hemopurifier device. The DSMB noted no safety concerns during their review of the second cohort, allowing the trial to proceed with further evaluations of safety and dosing. Enrollment for the final cohort is now open, with participants receiving three treatments over a week.
Read more →AEMDAethlon Medical Engages Maxim Group LLC to Evaluate Strategic Opportunities
Aethlon Medical has engaged Maxim Group LLC as its exclusive financial advisor to explore strategic opportunities, including potential partnerships and acquisitions. The company is also progressing with its oncology trial in Australia, having completed the second cohort. However, there is no set timeline for the evaluation process, and no guarantees exist regarding the outcome of these discussions.
Read more →AEMDAethlon Medical to Present on the Emerging Growth Conference on February 25th 2026
Aethlon Medical, Inc. will present at the Emerging Growth Conference on February 25, 2026. The event will feature a live interactive session with the CEO and CFO, allowing attendees to engage directly. The Hemopurifier, an investigational device for treating cancer and infectious diseases, holds a Breakthrough Device Designation from the FDA.
Read more →AEMDAethlon Medical Announces Fiscal Q3 2026 Financial Results and Corporate Update
Aethlon Medical reported its fiscal Q3 2026 financial results, highlighting ongoing clinical trials and cost efficiencies. The company is advancing its Hemopurifier technology, showing promise in cancer treatment and Long COVID research. Despite an increase in operating loss, Aethlon's commitment to clinical programs remains strong, with a focus on optimizing costs.
Read more →AEMDAethlon Medical to Release Fiscal Third Quarter Financial Results and Host Conference Call on February 12, 2026
Aethlon Medical, Inc. will announce its fiscal third quarter financial results on February 12, 2026, at 4:15 p.m. ET. A conference call will follow at 4:30 p.m. ET to discuss these results and recent corporate developments. The Hemopurifier, a key product, has received FDA Breakthrough Device designation for treating advanced cancer and life-threatening viral infections.
Read more →AEMD▲ +6.5%on this news
Aethlon Medical Announces Pricing of a Private Placement and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $3.3 Million
Aethlon Medical, Inc. has announced a private placement agreement with an institutional investor, aiming to raise approximately $3.3 million. The deal includes the sale of shares and warrants priced at $4.03 each. The offering is expected to close by December 8, 2025, pending customary conditions. The company plans to use the funds to further develop its Hemopurifier technology.
Read more →AEMD▼ -23.5%on this newsshared move
Aethlon Medical Announces Publication of Preclinical Data Showing That the GNA Affinity Resin in the Hemopurifier® Binds to Extracellular Vesicles in Long COVID patient samples and Decreases Inflammatory microRNAs
Aethlon Medical has published preclinical data indicating that its Hemopurifier can bind to extracellular vesicles in Long COVID patient samples, potentially decreasing inflammatory microRNAs. This study, conducted in collaboration with UCSF, suggests that the Hemopurifier may serve as a therapeutic option for Long COVID, which currently lacks effective treatments.
Read more →AEMD▲ +12.9%on this news
Aethlon Medical Announces Fiscal Q2 2025 Financial Results and Corporate Update
Aethlon Medical, Inc. reported its fiscal Q2 2025 financial results, highlighting significant progress in clinical trials and a 48% reduction in operating expenses. The company is advancing its Hemopurifier device in oncology trials, with recruitment for a second cohort underway. Despite positive developments, challenges remain, including the limited effectiveness of current therapies for patients.
Read more →AEMDAethlon Medical to Release Fiscal Second Quarter Financial Results and Host Conference Call on November 12, 2025
Aethlon Medical, Inc. will release its fiscal second quarter financial results on November 12, 2025, at 4:15 p.m. ET. Following this, a conference call will be held at 4:30 p.m. ET to discuss the results and recent corporate developments. The Hemopurifier, an investigational device, aims to treat advanced cancer and life-threatening viral infections.
Read more →AEMD▼ -5.8%on this news
Aethlon Medical's Hemopurifier® shows Changes in Extracellular Vesicles, Extracellular MicroRNAs, and T Cell Numbers in Australian Oncology Clinical Trial
Aethlon Medical reported preliminary changes in extracellular vesicles, microRNAs, and T cell numbers for three patients in an Australian oncology trial. The Hemopurifier device showed decreases in large EVs and PD-L1 in participants following a single treatment. Increases in total T cell counts were also noted in the small cohort. These early observations come from a safety and dose-finding study with limited follow-up data.
Read more →About Aethlon Medical, Inc.
Headquarters11555 SORRENTO VALLEY ROAD, SUITE 203, SAN DIEGO, CA, 92121
Founded1991
BIOPHARMAWATCH ELITE PLUS
Trade the next AEMD catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime